Condition: Metastatic Breast Cancer · Recurrent Ovarian Carcinoma · Sponsor: University of Utah
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination. The trial will open with a dose escalation followed by an expansion cohort at the identified dose. Dose escalation will be open to the enrollment of patients diagnosed with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients diagnosed with triple-negative breast cancer.
This description comes directly from the study's public registry record.
Janna Espinosa · 801-585-0571 · janna.espinosa@hci.utah.edu
Always discuss trial participation with your own doctor first.
| Huntsman Cancer Institute | Salt Lake City, Utah, United States | Recruiting |
| Inova Schar Cancer Institute | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04315233